CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to Learn
posted 18 hours
Mashup Score: 9
OncLive - Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have...
Next Steps in Small Cell Lung Cancer Feature Closer Eye on Immunotherapy, Lurbinectedin
posted 1 day
Mashup Score: 4
OncLive - Benjamin Drapkin, MD, PhD, discusses the road ahead in small cell lung cancer research, and the challenges that still need to be solved in...
Telehealth Is Here to Stay: Opportunities and Challenges for Cancer Care
posted 22 hours
Mashup Score: 2
OncLive - Oncology practices across the United States have rapidly increased telehealth use in 2020 to mitigate the risk of coronavirus disease 2019 (COVID-19) to patients...
TP53 Mutations Among Prognostic Factors Associated With Ibrutinib-Resistant CLL
posted 2 days
Mashup Score: 2
OncLive - Patients with chronic lymphocytic leukemia who are at an increased risk of failure on ibrutinib can be identified prior to treatment initiation using a...
Fight Cancer using your own T-Cells
posted 2 months
Despite recent advancements in immuno-oncology, not all patients with cancer benefit from current treatments, and additional therapeutic options are needed for both hematologic malignancies...
OncLive - The FDA has approved the FoundationOne CDx comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions...
OncLive - The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the...
OncLive - After 15 years as a surgeon, Jeffrey M. Farma, MD, says he’s still learning how to treat patients with cancer. As fellowship director of...
OncLive - Daniel P. Petrylak, MD, discusses the ever-changing prostate cancer armamentarium, as well as the role of biomarkers and new diagnostic methods in the...
OncLive - The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the...
MD Anderson and Taiho Pharmaceutical Collaborate to Develop Therapies for Brain Metastases
posted 13 hours
Mashup Score: 1
OncLive - The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical have formed a collaboration to do preclinical and early clinical research on potential...
With the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, lymphoma treatment has entered a new era. @BrianHill_MDPhD @ClevelandClinic #lymsm https://t.co/btesLm5drT